Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 4,934.00
-103.00 (-2.04%)
Jun 19, 2026, 3:30 PM JST
Revenue Breakdown 2
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
GI Revenue (Post-FY2024 Reporting) | 1.41T | 1.36T | ||||||||||||
GI Revenue (Post-FY2024 Reporting) Growth | 3.72% | 11.58% | ||||||||||||
Rare Diseases Revenue (Post-FY2024 Reporting) | 762.70B | 752.82B | ||||||||||||
Rare Diseases Revenue (Post-FY2024 Reporting) Growth | 1.31% | 9.35% | ||||||||||||
PDT Revenue (Post-FY2024 Reporting) | 1.06T | 1.03T | ||||||||||||
PDT Revenue (Post-FY2024 Reporting) Growth | 2.41% | 14.27% | ||||||||||||
Oncology Revenue (Post-FY2024 Reporting) | 580.13B | 560.43B | ||||||||||||
Oncology Revenue (Post-FY2024 Reporting) Growth | 3.51% | 21.21% | ||||||||||||
Vaccines Revenue | 59.61B | 55.41B | ||||||||||||
Vaccines Revenue Growth | 7.57% | 10.04% | ||||||||||||
Neuroscience Revenue (Post-FY2024 Reporting) | 414.34B | 565.82B | ||||||||||||
Neuroscience Revenue (Post-FY2024 Reporting) Growth | -26.77% | -9.76% | ||||||||||||
Other Product Revenue (Post-FY2024 Reporting) | 223.96B | 257.39B | ||||||||||||
Other Product Revenue (Post-FY2024 Reporting) Growth | -12.99% | -18.47% | ||||||||||||
Revenue (Total) | 4.51T | 4.58T | ||||||||||||
Revenue (Total) Growth | -1.65% | 7.45% |
Revenue by Geography
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 | Mar '16 Mar 31, 2016 | Mar '15 Mar 31, 2015 | Mar '14 Mar 31, 2014 | Mar '13 Mar 31, 2013 |
Japan Revenue | 433.11B | 418.46B | ||||||||||||
Japan Revenue Growth | 3.50% | -7.29% | ||||||||||||
United States Revenue | 2.16T | 2.38T | ||||||||||||
United States Revenue Growth | -9.03% | 8.38% | ||||||||||||
Europe and Canada Revenue | 1.15T | 1.06T | ||||||||||||
Europe and Canada Revenue Growth | 8.62% | 9.14% | ||||||||||||
Latin America Revenue | 254.13B | 235.85B | ||||||||||||
Latin America Revenue Growth | 7.75% | 19.05% | ||||||||||||
China Revenue | 195.14B | 191.74B | ||||||||||||
China Revenue Growth | 1.77% | 9.66% | ||||||||||||
Asia (ex-Japan & China) Revenue | 98.67B | 99.39B | ||||||||||||
Asia (ex-Japan & China) Revenue Growth | -0.73% | 15.07% | ||||||||||||
Asia (ex-Japan) Revenue | 293.81B | 291.13B | ||||||||||||
Asia (ex-Japan) Revenue Growth | 0.92% | 11.45% | ||||||||||||
Russia / CIS Revenue | 79.72B | 72.36B | ||||||||||||
Russia / CIS Revenue Growth | 10.18% | -0.33% | ||||||||||||
Other Geographic Revenue | 133.89B | 128.85B | ||||||||||||
Other Geographic Revenue Growth | 3.91% | 9.28% | ||||||||||||
Revenue (Other) | 2.00M | 3.00M | ||||||||||||
Revenue (Total) | 4.51T | 4.58T | ||||||||||||
Revenue (Total) Growth | -1.65% | 7.45% |